234080 — JW Life Science Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeSmall CapContrarian

Annual income statement for JW Life Science, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	169,817	188,931	206,860	222,478	257,829
Cost of Revenue
Gross Profit	49,157	48,121	52,393	57,508	72,317
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	141,315	161,842	176,009	186,620	224,585
Operating Profit	28,502	27,089	30,851	35,858	33,244
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	18,287	20,782	33,708	59,027	31,745
Provision for Income Taxes
Net Income After Taxes	12,914	14,961	28,144	43,988	28,606
Net Income Before Extraordinary Items
Net Income	12,914	14,961	28,144	43,988	28,606
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	12,914	14,961	28,144	43,988	28,606
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	841	967	1,827	2,841	1,844
Dividends per Share